News Briefing channel feed

GSK brings Johns Hop­kins prof and Blade co-founder on board; Evotec sets terms for $575M+ US IPO

4 years ago

ARCH-backed SciNeu­ro kicks off search for CNS au­toan­ti­bod­ies with new deal; Mer­ck + Gilead an­nounce PhII tri­al for HIV com­bo

4 years ago

Av­enue Ther­a­peu­tics lands an FDA ad­comm for trou­bled flag­ship drug; FDA ap­proves eye in­jec­tion treat­ment for flu­id buildup

4 years ago

Lian­Bio an­nounces terms for IPO next week; NIH and White House of­fi­cials dis­cuss hy­po­thet­i­cal bio-med re­search agency

4 years ago

J&J dives deep­er in­to bis­pecifics; Spring­Works an­nounces re­search deal over Stan­ford pro­fes­sor's work

4 years ago

Sage, Bio­gen head to FDA with $3.1B de­pres­sion drug; Sana puts down $50M to tap Beam's CRISPR tech

4 years ago

Langer, Ciechanover god­fa­ther the lat­est AI up­start; Ipsen forges $446M AML de­vel­op­ment pact

4 years ago

FDA ad­comm to de­cide on mol­nupi­ravir EUA; Can­cer at­las un­veils new po­ten­tial drug tar­get

4 years ago

Ex­elix­is, Storm join up in col­lab­o­ra­tion and li­cense agree­ment; Teligent files for bank­rupt­cy

4 years ago

Reg­u­lus dumps first-gen ADP­KD treat­ment in fa­vor of sec­ond it­er­a­tion; Sutro joins BioNo­va in $200M deal

4 years ago

In­hi­brx shares rise on PhI tri­al re­sults; Bragli­a's Helsinn en­ters part­ner­ship with Fo­s­un

4 years ago

Draw­ing Shire par­al­lel, Flem­ming Ørn­skov mulls IPO for Gal­der­ma; Rei­s­tone shows re­sults from eczema study with JAK1 block­er

4 years ago

Mi­rati teams with Sanofi on PhI/II tri­al for KRAS treat­ment com­bo; Ab­b­Vie los­es in lat­est Hu­mi­ra biosim­i­lar de­vel­op­ment

4 years ago

Schrödinger teams up with MD An­der­son on WEE1 in­hibitor pro­gram; Amid JAK safe­ty con­cerns, Ab­b­Vie touts new da­ta for Rin­voq 

4 years ago

Ae­tion to col­lab­o­rate with UK's NICE on RWE; 4D's cys­tic fi­bro­sis gene ther­a­py cleared for clin­i­cal tri­als

4 years ago

Ex-FDA of­fi­cials ask SCO­TUS to take up J&J talc case; An­no­vis shows da­ta from PhII Parkin­son's tri­al

4 years ago

As­traZeneca's En­her­tu gets BTD for breast can­cer; Centes­sa nabs $300M loan

4 years ago

At­las cre­ates sec­ond op­por­tu­ni­ty fund with $300M; BioN­Tech's col­orec­tal can­cer vac­cine starts PhII tri­al

4 years ago

Spero strikes $125M roy­al­ty deal for cU­TI drug; French firm launch­es $100M ear­ly biotech fund

4 years ago

Te­va set­tles with Louisiana for $18M over opi­oid claims; Video game treat­ment churns out PhII re­sults

4 years ago

French biotech and Pfiz­er find pos­i­tives in da­ta for Ly­me dis­ease vac­cine can­di­date; Al­tim­mune's obe­si­ty drug shows promise in PhI tri­al

4 years ago

Evelo touts PhII win for in­flam­ma­tion pro­gram; In­novent, An­Heart claim in­ter­im PhII suc­cess in NSCLC

4 years ago

Capri­cor's DMD clin­i­cal tri­al meets pri­ma­ry end­points; Delaware court rules against Take­da in Lupron feud

4 years ago

Ox­ford Bio­med­ica sees new in­vest­ment for man­u­fac­tur­ing; Twist gets a part­ner to help build out dis­cov­ery li­braries 

4 years ago
First page Previous page 26272829303132 Next page Last page
A service from the Financial Times